Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.
We have studied the ability of immunized lymphoid cells expanded in IL-2 to mediate the cure of mice with localized and disseminated syngeneic lymphoma. Mice received 500 rad total-body irradiation before injection of tumor into the footpad. Mice were treated 5 d later when a palpable local tumor and disseminated metastases were present. Intravenous injection of in vivo immune lymphocytes cured 93% of all mice, significantly better than any control group (P less than 0.0005). Immune cells, secondarily sensitized to the FBL-3 tumor in vitro, also conferred significant survival benefit (P less than 0.005) when injected intravenously, curing 79% of the animals treated. When these in vitro sensitized cells were expanded in IL-2, 8-10-fold over 7 d, 93% of the animals thus treated were cured, (P less than 0.005). When these cells were grown for multiple generations in IL-2 they retained their ability to cure mice (56% cured, P less than 0.01). This is the first demonstration that intravenous injection of sensitized cells grown in long term culture in IL-2 is capable of curing mice of established local and disseminated syngeneic tumor.
D000818:Animals; D002470:Cell Survival; D003602:Cytotoxicity, Immunologic; D005260:Female; D005354:Fibrosarcoma / Q000276:immunology / Q000628:therapy*; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology*; D007942:Leukemia, Experimental / Q000276:immunology / Q000628:therapy*; D017710:Lymphocyte Transfusion; D008222:Lymphokines / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D012513:Sarcoma, Experimental / Q000276:immunology / Q000628:therapy*; D013154:Spleen / Q000276:immunology; D014185:Transplantation, Isogeneic
D007376:Interleukin-2; D008222:Lymphokines